CD19 is expressed on B- lineage cells and follicular dendritic cells and plays a key role in B cell malignancies and autoimmune diseases. Thus, it has been considered as potential target for several monoclonal antibodies (mAbs).

Objective: This article summarizes the background, clinical trials, and place in therapy for the first two anti-CD19 monoclonal antibodies that have been recently FDA approved for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

CD19 monoclonal antibodies work by targeting the CD19 protein that is present on the surface of pre-B and mature B lymphocytes and overexpressed in several different cancers, including CD19-positive B-cell leukemias or lymphomas. CD19 monoclonal antibodies may have slightly different ways of working.

CD19 is a biomarker for normal and neoplastic B cells, as well as follicular dendritic cells. CD19 is critically involved in establishing intrinsic B cell signaling thresholds through modulating both B cell receptor-dependent and independent signaling.

Three anti-CD19 monoclonal antibodies with distinct mechanisms of action have been developed for the treatment of B-cell malignancies. Methods: We reviewed the preclinical and clinical data on the development of the newly approved anti-CD19 monoclonal antibodies blinatumomab, tafasitamab and loncastuximab tesirine, and consider their place in ...

2024年2月21日 · Here, we present data on the short- and long-term efficacy and safety of CD19 CAR T-cell treatment in 15 patients with severe forms of three distinct autoimmune diseases. Details on patient...

2021年11月6日 · We reviewed the preclinical and clinical data on the development of the newly approved anti-CD19 monoclonal antibodies blinatumomab, tafasitamab and loncastuximab tesirine, and consider their place in the treatment of relapsed or refractory B-cell malignancies.

2025年3月8日 · Anti-CD19 chimeric antigen receptor (CAR)-T cell therapy has shown promise in treating autoimmune diseases (AID) such as systemic lupus erythematosus, myositis, systemic sclerosis [3],...

Anti-CD19 CAR T-cells currently represent transformational therapy for relapsed/refractory aggressive B-cell lymphomas where durable remissions can be induced in patients with previously incurable chemotherapy-refractory disease.

CD19, in association with CD21 and CD81, forms a molecular complex integral to B cell activation. Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide. The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.